Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
RESEARCH TOOLSreports
NAMS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$15.19 - $27.29
Previous CloseN/A
Volume118.30K
Average Volume (3M)619.40K
Market Cap
$2.14B
Enterprise Value$1.15B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Mar 28, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding106,832,954
10 Day Avg. Volume515,681
30 Day Avg. Volume619,398
Standard Deviation0.20
R-Squared0.00015
Alpha0.06
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)56.46
Price to Cash Flow (P/CF)-37.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit90.16
Enterprise Value/Ebitda-6.70
Forecast
1Y Price Target
$45.25Price Target Upside136.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
NewAmsterdam Pharma Company News
PremiumCompany Announcements
NewAmsterdam Pharma Achieves Key Milestones in 2024
---
Bulls Say, Bears Say
Bulls Say
Commercial PotentialObicetrapib has strong commercial potential and a multifaceted mechanism of action, which could lead to broader therapeutic benefits beyond LDL lowering.
Financial PositionA strong YE24 (unaudited) cash position of ~$835M positions them well through both the Ph.2 VINCENT trial readout and potential obi commercial prep, including manufacturing readiness and inventory build-out for US / EU markets.
Trial ResultsThe unexpectedly clear MACE benefit in the Phase 3 BROADWAY trial is supported by obicetrapib's multifaceted mechanism, including robust Lp(a) reduction and potential diabetes benefits.
Bears Say
---
Ownership Overview
16.70% Insiders
0.80% Mutual Funds
65.57% Other Institutional Investors
16.17% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NAMS FAQ
What was NewAmsterdam Pharma Company’s price range in the past 12 months?
NewAmsterdam Pharma Company lowest stock price was $15.19 and its highest was $27.29 in the past 12 months.
What is NewAmsterdam Pharma Company’s market cap?
NewAmsterdam Pharma Company’s market cap is $2.14B.
When is NewAmsterdam Pharma Company’s upcoming earnings report date?
NewAmsterdam Pharma Company’s upcoming earnings report date is Mar 28, 2025 which is in 35 days.
How were NewAmsterdam Pharma Company’s earnings last quarter?
NewAmsterdam Pharma Company released its earnings results on Nov 06, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.499 by $0.319.
Is NewAmsterdam Pharma Company overvalued?
According to Wall Street analysts NewAmsterdam Pharma Company’s price is currently Undervalued.
Does NewAmsterdam Pharma Company pay dividends?
NewAmsterdam Pharma Company does not currently pay dividends.
What is NewAmsterdam Pharma Company’s EPS estimate?
NewAmsterdam Pharma Company’s EPS estimate is -0.49.
How many shares outstanding does NewAmsterdam Pharma Company have?
NewAmsterdam Pharma Company has 106,832,954 shares outstanding.
What happened to NewAmsterdam Pharma Company’s price movement after its last earnings report?
NewAmsterdam Pharma Company reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.499. Following the earnings report the stock price went up 13.734%.
Which hedge fund is a major shareholder of NewAmsterdam Pharma Company?
Currently, no hedge funds are holding shares in NAMS
---
NewAmsterdam Pharma Company Stock Smart Score
Company Description
NewAmsterdam Pharma Company
Frazier Lifesciences Acquisition Corp is a blank check company.
---
NAMS Stock 12 Month Forecast
Average Price Target
$45.25
▲(136.66% Upside)
Technical Analysis
Amarin
―
Madrigal Pharmaceuticals
―
Esperion
―
Viking Therapeutics
―
Akero Therapeutics
―
Best Analysts Covering NAMS
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
+32.64%
assigned a buy rating 3 months ago
Copying Dennis Ding's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +32.64% per trade.
---